Analysts Set TuHURA Biosciences, Inc. (NASDAQ:HURA) Target Price at $9.00

TuHURA Biosciences, Inc. (NASDAQ:HURA) has been assigned a consensus recommendation of “Moderate Buy” from the six ratings firms that are presently covering the firm, MarketBeat reports. One analyst has rated the stock with a sell recommendation and five have issued a buy recommendation on the company. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $9.00.

A number of analysts have recently issued reports on the company. Citigroup started coverage on TuHURA Biosciences in a research report on Monday, April 27th. They set an “outperform” rating for the company. Weiss Ratings restated a “sell (e+)” rating on shares of TuHURA Biosciences in a research report on Friday, July 17th. Rodman & Renshaw initiated coverage on shares of TuHURA Biosciences in a research note on Wednesday, April 15th. They issued a “buy” rating on the stock. Wall Street Zen lowered shares of TuHURA Biosciences from a “hold” rating to a “sell” rating in a research report on Sunday, May 31st. Finally, Citizens Jmp assumed coverage on shares of TuHURA Biosciences in a research note on Monday, April 27th. They issued a “market outperform” rating and a $9.00 price target for the company.

Institutional Trading of TuHURA Biosciences

Hedge funds have recently made changes to their positions in the stock. Virtu Financial LLC purchased a new position in TuHURA Biosciences in the third quarter worth $26,000. JPMorgan Chase & Co. purchased a new stake in TuHURA Biosciences during the second quarter valued at about $27,000. Wells Fargo & Company MN raised its position in TuHURA Biosciences by 109.0% during the fourth quarter. Wells Fargo & Company MN now owns 38,208 shares of the company’s stock valued at $29,000 after purchasing an additional 19,931 shares in the last quarter. Goldman Sachs Group Inc. purchased a new stake in TuHURA Biosciences during the fourth quarter valued at about $30,000. Finally, Invesco Ltd. bought a new stake in TuHURA Biosciences during the second quarter worth about $30,000. 0.62% of the stock is owned by institutional investors.

TuHURA Biosciences Stock Performance

NASDAQ:HURA opened at $2.11 on Friday. The firm has a market capitalization of $134.36 million, a price-to-earnings ratio of -3.46 and a beta of -0.05. TuHURA Biosciences has a 52-week low of $0.41 and a 52-week high of $3.90. The stock has a fifty day moving average of $2.32 and a 200 day moving average of $1.85.

TuHURA Biosciences (NASDAQ:HURA) last posted its earnings results on Friday, May 15th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.01). Equities analysts forecast that TuHURA Biosciences will post -0.56 earnings per share for the current fiscal year.

About TuHURA Biosciences

TuHURA Biosciences is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics using high‐dimensional proteomics. The company’s core mission is to translate complex protein signatures into actionable drug targets across a range of disease areas. By integrating proteomic data with advanced computational analytics, TuHURA aims to bridge the gap between molecular disease understanding and the development of first‐in‐class therapies.

At the heart of TuHURA’s approach is its proprietary platform, which leverages multiplexed protein profiling to generate rich phenotypic maps of disease states.